Alphamab Oncology (9966.HK)

HKD 7.85

(21.52%)

Long Term Debt Summary of Alphamab Oncology

  • Alphamab Oncology's latest annual long term debt in 2023 was 176.58 Million CNY , up 17.72% from previous year.
  • Alphamab Oncology's latest quarterly long term debt in 2024 Q2 was 150 Million CNY , down 0.0% from previous quarter.
  • Alphamab Oncology reported annual long term debt of 150 Million CNY in 2022, down -2.49% from previous year.
  • Alphamab Oncology reported annual long term debt of 153.82 Million CNY in 2021, up 620.5% from previous year.
  • Alphamab Oncology reported quarterly long term debt of 176.58 Million CNY for 2023 Q4, down 0.0% from previous quarter.
  • Alphamab Oncology reported quarterly long term debt of 176.58 Million CNY for 2023 FY, up 17.72% from previous quarter.

Annual Long Term Debt Chart of Alphamab Oncology (2023 - 2017)

Historical Annual Long Term Debt of Alphamab Oncology (2023 - 2017)

Year Long Term Debt Long Term Debt Growth
2023 176.58 Million CNY 17.72%
2022 150 Million CNY -2.49%
2021 153.82 Million CNY 620.5%
2020 21.35 Million CNY -89.9%
2019 211.34 Million CNY 110.26%
2018 100.51 Million CNY 0.0%
2017 - CNY 0.0%

Peer Long Term Debt Comparison of Alphamab Oncology

Name Long Term Debt Long Term Debt Difference
Uni-Bio Science Group Limited 30.61 Million HKD -476.839%
CK Life Sciences Int'l., (Holdings) Inc. 4.27 Billion HKD 95.867%